NOVO NORDISK - DOUBLING THE AMOUNT OF THE LOWER DOSE STRENGTHS OF WEGOVY INTO THE U.S. MARKET BEGINNING IN JANUARY OF 2024
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
970 DKK | +0.26% | -3.25% | +38.95% |
07-04 | ETF of the week: Investing in strong trends with the momentum theme | |
07-04 | NOVO NORDISK : Deutsche Bank remains its Buy rating | ZD |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.95% | 621B | |
+54.07% | 809B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.21% | 238B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B | |
-3.79% | 157B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk - Doubling The Amount Of The Lower Dose Strengths…